<DOC>
	<DOC>NCT00410696</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.</brief_summary>
	<brief_title>Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy</brief_title>
	<detailed_description>Secondary objective is to evaluate the immunological reconstitution after pegfilgrastim and filgrastim.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients with hematological neoplasms or solid tumors candidable to highdose chemotherapy with autologous peripheral stem cell reinfusion Adequate organ function Written informed consent. Use of other experimental drugs Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>High-dose chemotherapy</keyword>
	<keyword>Growth factor</keyword>
	<keyword>Pegfilgrastim</keyword>
</DOC>